摘要
大规模随机临床试验和荟萃分析证明,绝大多数淋巴结阳性乳腺癌病人需要辅助化疗。合适的化疗方案、剂量强度和周期数都是影响疗效的重要因素,剂量密度化疗进一步提高了疗效。分子标志物不仅可预示淋巴结阳性乳腺癌病人的预后,在将来还可以指导乳腺癌的个体化治疗。
The status of lymph node is one of the most important prognostic factors of patients with breast cancer.Patients who present with positive lymphnodes have higher risk of relapse and metastasis.Adjuvant chemotherapy may prolong disease-free survival and overall survival rate of patients with node-positive breast cancer.The majority of these patients are advised to accept adjuvant chemotherapy.At present,CMF regimen,anthracycline-based regimen and taxanes-based regimen are in common use.Appropriate dose-intensity and the number of cycles might be determinants of treatment outcome.Dose-dense chemotherapy further improves the efficacy of chemotherapy in patients with breast cancer.Molecular makers not only may predict the prognosis of patients with node-positive breast cancer,but also guide tailored chemotherapy in the future.
出处
《癌症进展》
2005年第3期232-236,共5页
Oncology Progress
关键词
乳腺癌
淋巴结阳性
辅助化疗
breast neoplasm node-positive adjuvant chemotherapy
